Condition: Hepatitis B · Cirrhosis, Liver · Chronic Liver Disease · Sponsor: Mercy Medical Center
Investigators want to compare the seroconversion rates between two-dose and three-dose regimens of the hepatitis B vaccine (Heplisav B) among patients with cirrhosis, a randomized prospective study.
This description comes directly from the study's public registry record.
CHAU TO, MD · (714)-400-1331 · cto@mdmercy.com
Paul Thuluvath, MD · (410)-332-9308 · pthuluv@mdmercy.com
Always discuss trial participation with your own doctor first.
| Mercy Medical Center | Baltimore, Maryland, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04588077